文献速递淋巴瘤造血干细胞移植与细胞治疗

钇-90标记抗CD25抗体联合BEAM方案作为外周T细胞淋巴瘤自体造血干细胞移植预处理

Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

这项1期临床试验在外周T细胞淋巴瘤(PTCL)患者中,将β发射体钇-90(90Y)标记的嵌合抗CD25巴利昔单抗(aTac)加入BEAM方案作为自体造血干细胞移植(AHCT)预处理。23例符合AHCT条件的患者入组,20例接受了治疗性90Y-aTac-BEAM AHCT。测试的辐射剂量为0.4、0.5和0.6 mCi/kg,未观察到剂量限制性毒性,0.6 mCi/kg被确定为推荐的2期剂量。

要点

  • 23例PTCL患者入组,20例接受90Y-aTac-BEAM AHCT,测试剂量0.4、0.5、0.6 mCi/kg。
  • 未观察到剂量限制性毒性,0.6 mCi/kg被确定为推荐的2期剂量。
  • 接受治疗性AHCT患者2年无进展生存率59%(95%CI 34-77),总生存率68%(95%CI 42-84)。

核心结论

  • 90Y-aTac-BEAM作为PTCL患者AHCT预处理方案似乎是安全的,毒性较既往单用BEAM未见增加。

研究设计与样本

  • 1期临床试验,入组23例符合AHCT条件的PTCL患者,其中20例接受治疗性90Y-aTac-BEAM AHCT。
  • 预处理方案为β发射体90Y标记的嵌合抗CD25巴利昔单抗(aTac)联合BEAM(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)。
  • 测试辐射剂量为0.4、0.5和0.6 mCi/kg。
  • 试验注册号NCT02342782。

主要发现

  • 未观察到剂量限制性毒性,0.6 mCi/kg被确定为推荐的2期剂量。
  • 最常见不良事件为2级黏膜炎,80%的患者发生。
  • 截至报告时,6例(30%)接受治疗的患者死亡,5例死于疾病进展,1例死于多器官衰竭,AHCT后中位死亡时间17个月(范围9-21)。
  • 中位随访时间总体为24个月(范围9-26),存活患者为24个月(范围13-26)。
  • 接受治疗性90Y-aTac-BEAM AHCT的患者,2年无进展生存率为59%(95%CI 34-77),2年总生存率为68%(95%CI 42-84)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission with first-line therapy, as well as in chemotherapy-sensitive relapse if allogeneic transplant is not an option. CD25 is a targetable protein often highly expressed in PTCLs. In this phase 1 clinical trial, we tested the addition of β-emitting 90yttrium (90Y)-labeled chimeric anti-CD25 basiliximab (aTac) to BEAM (carmustine, etoposide, cytarabine, and melphalan) as conditioning for AHCT for patients with PTCL. Twenty-three AHCT-eligible patients were enrolled, and 20 received therapeutic 90Y-aTac-BEAM AHCT. Radiation doses of 0.4, 0.5, and 0.6 mCi/kg were tested. With no observed dose-limiting toxicities, 0.6 mCi/kg was deemed the recommended phase 2 dose. The most prevalent adverse effect, grade 2 mucositis, was experienced by 80% of patients. As of this report, 6 (30%) of the treated patients had died, 5 due to progressive disease and 1 due to multiple organ failure (median time of death, 17 months [range, 9-21]) after AHCT. Median follow-up was 24 months (range, 9-26) overall and 24 months (range, 13-26) for surviving patients. For patients who received therapeutic 90Y-aTac-BEAM AHCT, the 2-year progression-free and overall survival were 59% (95% confidence interval [CI], 34-77) and 68% (95% CI, 42-84), respectively. 90Y-aTac-BEAM appears to be safe as an AHCT conditioning regimen for PTCL, with no increased toxicity over the toxicities historically seen with BEAM alone in this patient population. This trial was registered at www.ClinicalTrials.gov as #NCT02342782.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zain J, Tsai NC, Palmer J, et al. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma. Blood Adv. 2024. PMID: 38838232. doi:10.1182/bloodadvances.2023012497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。